Pharma Industry Divided Over Trump's Accelerated Drug Review Program

Pharmaceutical companies are divided over the Trump administration's faster review process for critical drugs, with concerns over potential legal risks and the future credibility of FDA decisions. The program promises approvals in one to two months, sparking debate on its impact and sustainability.

The pharmaceutical industry is grappling with mixed reactions to the Trump administration's accelerated drug review program, which seeks to expedite approvals for critical medicines. While some major drugmakers embrace the initiative, others remain cautious due to potential legal risks and its impact on the FDA's credibility, Reuters reports.

Under the National Priority Voucher Program, launched by FDA Commissioner Marty Makary, certain key drugs could receive U.S. Food and Drug Administration approval within one to two months. This program aims to bolster public health or national security, emphasizing American-made or low-cost medicines. Such rapid reviews have sparked concern within the industry about maintaining scientific rigor.

The program has already issued vouchers for 18 drugs, according to Reuters. Nonetheless, some executives worry about the program's longevity and the potential challenges to FDA approvals. The initiative has exposed deeper issues within the agency, including a perceived politicization, lack of transparency, and pressure for expedited results.

(With inputs from agencies.)